Bangkok
,
Thailand and on-demand
22 - 26 June 2024
International Society on Thrombosis and Haemostasis, 2024 (ISTH)
Presentation schedule and materials
The congress symposium is no longer available
Saturday, 22 June 2024
ORAL PRESENTATION
Use of artificial intelligence to guide untrained individuals performing self-ultrasound scans of the knee joint
Nima Teimouri1; Daniel Michelsanti1; Peter Waede Hansen1; Susan Kras2; Johannes Roth3; Lars Bryup1; Marek Zak1
MATERIALS AVAILABLE
Sunday, 23 June 2024
ORAL PRESENTATION
Efficacy and Safety of Mim8 prophylaxis in adults and adolescents with Hemophilia A with or without Inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study
Maria Elisa Mancuso1; Tadashi Matsushita2; Pratima Chowdary3; Steven R Lentz4; Johnny Mahlangu5; Chandrakala Shanmukhaiah6; Ilgiz Rakhmatullin7; Pernille Juul Jørgensen7; Johannes Oldenburg8
POSTER
Treatment satisfaction and joint health outcomes within a real-world haemophilia B population: the Adelphi Disease Specific Programme™ survey
Victor Jiménez-Yuste1; Cléa Percier2; Thomas Porstmann2; Nathan Ball3; Giancarlo Castaman4
POSTER
Comparison of FVIII and concizumab in thrombin generation assays under different conditions
Jacob Lund1; Marianna Kjalke1
ORAL PRESENTATION
Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A
Jacob Lund1; Jais Rose Bjelke1; Daniele Granata1; Thomas Egebjerg1; Eva Johansson1; Wang Zhuoran1; Pierre-Louis Bardonnet1; Pingping Chen1; Mads Bjelke1; Andreas Vegge1
Monday, 24 June 2024
POSTER
Interim results from a non-interventional, post authorisation safety study of nonacog beta pegol as routine prophylaxis in patients with haemophilia B
Davide Matino1; Mette Joost Kragh2; Andrea Landorph2; Robert Klamroth3
POSTER
Clinical outcomes of people with hemophilia B treated with N9-GP in real-world settings: the Adelphi Disease Specific Programme™ hemophilia study
Giancarlo Castaman1; Cléa Percier2; Nathan Ball3; Víctor Jiménez-Yuste4; Shwetha Prashanth5*
ORAL PRESENTATION
Concizumab efficacy results at 56-week cut-off in patients with hemophilia A/B without inhibitors: an intra-patient analysis from the phase 3 explorer8 study
Anthony K Chan1; Pratima Chowdary2; Hermann Eichler3; Amalie Rhode Høgh Nielsen4; Jay Jay Thaung Zaw4; Guy Young5; Pantep Angchaisuksiri6
ORAL PRESENTATION
Management of breakthrough bleeding episodes in the phase 3 concizumab studies
Johnny Mahlangu1; Giancarlo Castaman2; Aby Abraham3; Jan Astermark4; Huyen Tran5,6; Chunduo Shen7; Julien Bovet7; Jameela Sathar8
Tuesday, 25 June 2024
ORAL PRESENTATION
Incidence of thromboembolic events among women with severe post-partum hemorrhage treated with recombinant activated factor VII: a systematic literature review and meta-analysis
Johanna van der Bom1; Frédéric J. Mercier2; Damaris Bausch-Fluck3; Mads Nordentoft4; Morten Medici4; Rezan Abdul-Kadir5,6
ORAL PRESENTATION
FVIII In Vitro Bioequivalence of Mim8 Haemostatic Effect by Thrombin Generation Assays
Jacob Lund1; Kasper Jensen2; David Lillicrap3; Mirella Ezban1
Keywords